Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 5, 2011, Pages 987-996

  Lee, K N ^a   Jackson, K W ^a   Christiansen, V J ^a   Dolence, E K ^b   Mckee, P A ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WYOMING   (United States)

Author keywords

2 antiplasmin; Antiplasmin cleaving enzyme inhibitor; Fibrinolysis; Fibroblast activation protein; Prolyl oligopeptidase; Z Pro prolinal insensitive peptidase

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIPLASMIN CLEAVING ENZYME; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; FIBRIN; METHIONINE; PHOSPHATE BUFFERED SALINE; PLASMIN; PROLYL ENDOPEPTIDASE; SEPRASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BLOOD CLOT LYSIS; FIBRINOLYSIS; HUMAN; IC 50; PRIORITY JOURNAL;

ALPHA-2-ANTIPLASMIN; FIBRINOLYSIS; GELATINASES; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MEMBRANE PROTEINS; PEPTIDES; PROTEIN PRECURSORS; SERINE ENDOPEPTIDASES; SOLUBILITY; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 79955654071     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04195.x     Document Type: Article

References (44)

1. 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 1982; 257: 14767-72.
2. 2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103: 3783-8.
3. 2-plasmin inhibitor in human plasma. Biochem J 1993; 291: 623-5.
4. 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun 1994; 200: 417-22.
5. Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006; 107: 1397-404.
6. Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Why alpha-antiplasmin must be converted to a derivative form for optimal function. J Thromb Haemost 2007; 5: 2095-104.
7. Lee KN, Jackson KW, Terzyan S, Christiansen VJ, McKee PA. Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design. Biochemistry 2009; 48: 5149-58.
8. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999; 274: 36505-12.
9. Rudy JL. Differentiating between sensitivity and limit of detection. Clin Chem 1989; 35: 509.
10. Venalainen JI, Juvonen RO, Forsberg MM, Garcia-Horsman A, Poso A, Wallen EA, Gynther J, Mannisto PT. Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. Biochem Pharmacol 2002; 64: 463-71.
11. Edosada CY, Quan C, Wiesmann C, Tran T, Sutherlin D, Reynolds M, Elliott JM, Raab H, Fairbrother W, Wolf BB. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J Biol Chem 2006; 281: 7437-44.
12. Gutheil WG, Bachovchin WW. Separation of L-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight-binding inhibition. Biochemistry 1993; 32: 8723-31.
13. Gorrao SS, Hemerly JP, Lima AR, Melo RL, Szeltner Z, Polgar L, Juliano MA, Juliano L. Fluorescence resonance energy transfer (FRET) peptides and cycloretro-inverso peptides derived from bradykinin as substrates and inhibitors of prolyl oligopeptidase. Peptides 2007; 28: 2146-54.
14. Tran T, Quan C, Edosada CY, Mayeda M, Wiesmann C, Sutherlin D, Wolf BB. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP. Bioorg Med Chem Lett 2007; 17: 1438-42.
15. Birney YA, O'Connor BF. Purification and characterization of a Z-pro-prolinal-insensitive Z-Gly-Pro-7-amino-4-methyl coumarin-hydrolyzing peptidase from bovine serum - a new proline-specific peptidase. Protein Expr Purif 2001; 22: 286-98.
16. Collins PJ, McMahon G, O'Brien P, O'Connor B. Purification, identification and characterisation of seprase from bovine serum. Int J Biochem Cell Biol 2004; 36: 2320-33.
17. Breen G, Harwood AJ, Gregory K, Sinclair M, Collier D, St Clair D, Williams RSB. Two peptidase activities decrease in treated bipolar disorder not schizophrenic patients. Bipolar Disord 2004; 6: 156-61.
18. Goossens F, De Meester I, Vanhoof G, Scharpe S. A sensitive method for the assay of serum prolyl endopeptidase. Eur J Clin Chem Clin Biochem 1992; 30: 235-8.
19. Maes M, Goossens F, Scharpe S, Meltzer HY, D'Hondt P, Cosyns P. Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. Biol Psychiatry 1994; 35: 545-52.
20. Maes M, Goossens F, Scharpe S, Calabrese J, Desnyder R, Meltzer HY. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res 1995; 58: 217-25.
21. Maes M, Lin AH, Bonaccorso S, Goossens F, van Gastel A, Pioli R, Delmeire L, Scharpe S. Higher serum prolyl endopeptidase activity in patients with post-traumatic stress disorder. J Affect Disord 1999; 53: 27-34.
22. Maes M, Monteleone P, Bencivenga R, Goossens F, Maj M, van West D, Bosmans E, Scharpe S. Lower serum activity of prolyl endopeptidase in anorexia and bulimia nervosa. Psychoneuroendocrinology 2001; 26: 17-26.
23. Momeni N, Nordstrom BM, Horstmann V, Avarseji H, Sivberg BV. Alterations of prolyl endopeptidase activity in the plasma of children with autistic spectrum disorders. BMC Psychiatry 2005; 5: 27.
24. Szeltner Z, Polgar L. Structure, function and biological relevance of prolyl oligopeptidase. Curr Protein Pept Sci 2008; 9: 96-107.
25. Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, Sharpe S, De M. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000; 267: 5608-13.
26. 2-antiplasmin activity. Blood 2007; 109: 5286-92.
27. Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen VJ, McKee PA, Egleston B, Cohen Sj, Weiner LM, Meropol NJ, Cheng JD. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol Ther 2007; 6: 1691-9.
28. Kelly TA, Adams J, Bachovchin WW, Barton RW, Campbell SJ, Coutts SJ, Kennedy CA, Snow RJ. Immunosuppressive boronic acid dipeptides: correlation between conformation and activity. J Am Chem Soc 1993; 115: 12637-8.
29. Nachman RL. Thrombosis and atherogenesis: molecular connections. Blood 1992; 79: 1897-906.
30. Nordt TK, Bode C. Endothelium and endogenous fibrinolysis. Z Kardiol 2000; 89: 219-26.
31. Smith EB, Thompson WD, Crosbie L, Stirk CM. Fibrinogen/fibrin in atherogenesis. Eur J Epidemiol 1992; 8(Suppl 1): 83-7.
32. Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res 1994; 73: 1-19.
33. Willeit J, Kiechl S. Biology of arterial atheroma. Cerebrovasc Dis 2000; 10(Suppl 5): 1-8.
34. Coughlin PB. Antiplasmin: the forgotten serpin? FEBS J 2005; 272: 4852-7.
35. 2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 2008; 14: 1250-4.
36. 2-plasmin inhibitor deficiencies: a review. Br J Haematol 2001; 114: 4-10.
37. Santos AM, Jung J, Aziz N, Kissil JL, Pure E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 2009; 119: 3613-25.
38. Lawandi J, Gerber-Lemaire S, Juillerat-Jeanneret L, Moitessier N. Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem 2010; 53: 3423-38.
39. Polgar L. The prolyl oligopeptidase family. Cell Mol Life Sci 2002; 59: 349-62.
40. Tenorio-Laranga J, Venalainen JI, Mannisto PT, Garcia-Horsman JA. Characterization of membrane-bound prolyl endopeptidase from brain. FEBS J 2008; 275: 4415-27.
41. Goossens F, De Meester I, Vanhoof G, Scharpe S. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin Chem Clin Biochem 1996; 34: 17-22.
42. Myohanen TT, Venalainen JI, Garcia-Horsman JA, Piltonen M, Mannisto PT. Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem Cell Biol 2008; 130: 993-1003.
43. Ahmed MM, Arif M, Chikuma T, Kato T. Pentylenetetrazol-induced seizures affect the levels of prolyl oligopeptidase, thimet oligopeptidase and glial proteins in rat brain regions, and attenuation by MK-801 pretreatment. Neurochem Int 2005; 47: 248-59.
44. Wolf BB, Quan C, Tran T, Wiesmann C, Sutherlin D. On the edge of validation - cancer protease fibroblast activation protein. Mini Rev Med Chem 2008; 8: 719-27.